Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-PAH: Triple Therapy vs Sildenafil Optimization in PAH
NCT07713914Phase 4Recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iloprost, selexipag and ASP-001 in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoint: Improvement in Risk Stratification According to the COMPERA 2.0 Four-Stratum Model. Started Jul 2026; status: recruiting.
02
Drugs
iloprostselexipagASP-001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07713914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07713914.